275 completed, 21 terminated, 18 recruiting, 18 unknown. 355 Phase 1, 65 Phase 2.
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| cfMSC Stem Cell Therapy Targeting COPD clonal fetal MSCs - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations Metformin - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Not yet recruiting | Duke University | 45 | 2027-02-01 | 2026-11-03 |
| The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD Inhaled Nitric Oxide, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Not yet recruiting | University of Alberta | 80 | 2026-12-01 | 2026-07-08 |
| A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment RSS0343 Tablet - Non-cystic Fibrosis Bronchiectasis, Chronic Sinusitis Without Nasal Polyps | Phase 1 | Not yet recruiting | Reistone Biopharma Company Limited | 24 | 2026-11-01 | 2026-11-17 |
| A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease RO7830698, Placebo - Chronic Obstructive Pulmonary Disease (COPD), Healthy Participants | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 104 | 2026-10-28 | 2026-11-13 |
| A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease Stem cells - Chronic Obstructive Lung Disease | Phase 1 / Phase 2 | Not yet recruiting | SMSbiotech | 125 | 2026-10-01 | 2026-10-13 |
| Phase 1 PK Study of AERO-007, an Inhaled LABA+LAMA Combination for Nebulization Delivery in COPD Patients AERO-002 (60 mcg), Glycopyrrolate (18 mcg) - COPD (Chronic Obstructive Pulmonary Disease) | Phase 1 | Completed | AeroRx Therapeutics Inc. | 24 | 2026-09-21 | 2026-10-15 |
| A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD R-3750 - COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation | Phase 1 | Not yet recruiting | Rise Therapeutics LLC | 27 | 2026-09-01 | 2026-01-29 |
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants GSK3862995B - Pulmonary Disease, Chronic Obstructive | Phase 1 | Recruiting | GlaxoSmithKline | 24 | 2026-08-18 | 2026-09-01 |
| A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of KIT2014 in Patients With Moderate to Severe COPD KIT2014, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 / Phase 2 | Recruiting | Kither Biotech Srl | 36 | 2026-08-05 | 2026-10-20 |
| A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD HRS-9821 Powder for Inhalation, Placebo - COPD | Phase 1 | Recruiting | Guangdong Hengrui Pharmaceutical Co., Ltd | 48 | 2026-07-09 | 2026-07-20 |
| Impact of Eradication Therapy on Helicobacter Pylori Infection With Chronic Obstructive Pulmonary Disease: Eradication of Helcobacter Pylori - Chronic Obstructive Pulmonary Disease (COPD), With Poitive H Pylori | Phase 1 | Recruiting | Zagazig University | 54 | 2026-03-01 | 2026-11-05 |
| Inhaled RB042 in Healthy Adult Volunteers, Healthy Adult Smokers and Patients With Chronic Obstructive Pulmonary Disease RB042, Placebo inhalation solution - Healthy, Healthy Smoker | Phase 1 | Recruiting | Atisama Therapeutics | 105 | 2026-02-16 | 2026-08-12 |
| A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd. | 33 | 2025-11-25 | 2026-08-27 |
| A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD) BBT002, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Recruiting | Bambusa Therapeutics | 68 | 2025-09-05 | 2026-07-22 |
| A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD. HRS-9821 Powder for Inhalation/HRS-9821 inhalation suspension, HRS-9821 Powder for Inhalation placebo/HRS-9821 inhalation suspension placebo, Moxifloxacin Hydrochloride Tablets - COPD | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 85 | 2025-08-11 | 2026-09-09 |
| The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations XH-S004 20 mg, 40 mg or 60 mg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 81 | 2025-07-15 | 2026-09-25 |
| Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD). Stem cells - Chronic Obstructive Lung Disease | Phase 1 | Recruiting | SMSbiotech | 18 | 2025-06-13 | 2026-08-11 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry GSK3862995B, Placebo - Pulmonary Disease, Chronic Obstructive | Phase 1 | Completed | GlaxoSmithKline | 30 | 2025-05-20 | 2026-06-11 |
| A Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) BBT002, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Recruiting | Bambusa Therapeutics | 286 | 2025-05-08 | 2026-07-01 |
Showing 20 of 355. Sign in to see all of them.
Asthma (45) · Emphysema (18) · Lung Diseases (14) · Respiratory Aspiration (11) · Pulmonary Emphysema (8) · Respiration Disorders (7) · Cystic Fibrosis (6) · Heart Failure (5) · Hypertension, Pulmonary (5) · Inflammation (5) · Dyspnea (4) · Motor Activity (4) · Renal Insufficiency (4) · Bronchitis, Chronic (3)
Chronic Disease (355) · Disease Attributes (355) · Pathological Conditions, Signs and Symptoms (355) · Pathologic Processes (353) · Lung Diseases, Obstructive (352) · Respiratory Tract Diseases (352) · Lung Diseases (341) · Bronchial Diseases (50) · Immune System Diseases (50) · Hypersensitivity (46) · Hypersensitivity, Immediate (45) · Respiratory Hypersensitivity (45) · Respiration Disorders (20) · Cardiovascular Diseases (11) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)
Tiotropium Bromide (14) · Budesonide (11) · Glycopyrrolate (11) · Inhalation (8) · Formoterol Fumarate (7) · GSK573719 (7) · Fluticasone (6) · Moxifloxacin (6) · Albuterol (5) · danirixin (5) · olodaterol (5) · Beclomethasone (4) · Charcoal (4) · Ciprofloxacin (4) · Itraconazole (4)
GlaxoSmithKline (84) · AstraZeneca (32) · Chiesi Farmaceutici S.p.A. (25) · Pearl Therapeutics, Inc. (8) · Boehringer Ingelheim (7) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (6) · Novartis (6) · Pfizer (6) · Aeris Therapeutics (5) · Bayer (5) · Intech Biopharm Ltd. (5) · Pulmatrix Inc. (4) · Theravance Biopharma (4) · Guangdong Hengrui Pharmaceutical Co., Ltd (3) · Hal C Charles (3)
United States (103) · United Kingdom (96) · Germany (43) · China (30) · Australia (20) · Belgium (11) · New Zealand (8) · Japan (7) · France (6) · Netherlands (6) · Austria (5) · Brazil (5) · Sweden (5) · Taiwan (5) · Bulgaria (4)
Dave Singh, MD (4) · Stuart Mair, MD (4) · Cecil Charles, PhD (3) · Chadwick Orevillo (3) · Carin Jorup (2) · Christian M Kaehler, MD (2) · Colin Reisner, M.D. (2) · Emma Harrop (2)
PMID 22793945, PMID 33152467, PMID 16235359, PMID 16565429, PMID 16636091, PMID 16690673, PMID 17132052, PMID 17507545, PMID 18073405, PMID 21975749, PMID 22314182, PMID 22793939, PMID 23074435, PMID 23076942, PMID 23235687, PMID 23256721, PMID 23364286, PMID 2337756, PMID 23992090, PMID 24563632, PMID 24615270, PMID 25450456, PMID 26092545, PMID 26372465, PMID 26372467, PMID 26620151, PMID 29149867, PMID 30425469, PMID 32071044, PMID 32907575, PMID 40391696, PMID 41677208, PMID 12493340, PMID 12543832, PMID 16611654, PMID 19164344, PMID 19436683, PMID 19643947, PMID 19750190, PMID 19880675, PMID 20920189, PMID 20979675, PMID 21311694, PMID 21474911, PMID 21615886, PMID 21852337, PMID 22075481, PMID 22374920, PMID 22465313, PMID 22760901
2015 (7), 2017 (5), 2023 (5), 2008 (3), 2018 (3), 2009 (2), 2014 (2), 2016 (2), 2019 (1), K76AG095138 (1), R01HL096471 (1), R01NR008938 (1), R01NR012009 (1), R03NR009361 (1), R21AT007357 (1)